---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-21-000168"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:34:31.634524+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance

## Summary
- Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).
- Reported EPS $1.53 (-1% YoY) due to $423M COVID antibody inventory charge.
- 2021 GAAP EPS guidance updated to $6.73-$6.93; non-GAAP unchanged at $7.80-$8.00.
- Key products: Trulicity +25%, Taltz +44%, Verzenio +64%; pipeline milestones for tirzepatide, Jardiance, donanemab.
- Board authorizes $5B share repurchase; acquires Protomer; global collaboration with MiNA.

## SEC filing metadata
- accession: 0000059478-21-000168
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/0000059478-21-000168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/lly-20210803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-21-000168
- JSON: https://secwatch.observer/filing/0000059478-21-000168.json
- Plain text: https://secwatch.observer/filing/0000059478-21-000168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.